Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Pharmacological research
2024
|
| Sujets: | |
| Accès en ligne: | https://pubmed.ncbi.nlm.nih.gov/39393436/ |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- Kallikrein inhibitor derived from immunoglobulin heavy chain junction region possesses anti-thromboinflammation potential. Yang, Juan Li, Ziyu Deng, Xinyi Li, Mengru Li, Bin Thuku, Rebecca Caroline Chen, Qian Sun, Xiang Lu, Qiumin Fang, Mingqian Animals Male Mice Anti-Inflammatory Agents Mice, Inbred C57BL Humans Thrombosis Inflammation Plasma Kallikrein Infarction, Middle Cerebral Artery Influenza vaccination is associated with a reduced incidence of cardiovascular events, cardiovascular death, and all-cause mortality. However, the functional role of the associated immunoglobulin remains unclear. This study identified a specific influenza-related immunoglobulin heavy chain junction region sequence (Ser-Leu-Gly-Ala-Ser-Asp, SD6) that inhibited plasma kallikrein (PKa) activity to resist thromboinflammatory responses and stroke injury. PKa is considered an attractive therapeutic target for alleviating the complications of thrombophilia-induced inflammation. In vitro, SD6 prolonged plasma recalcification and activated partial thromboplastin time, with no effects on bleeding risk-related prothrombin time, indicating selective inhibition of the intrinsic coagulation pathway. Correspondingly, at doses ranging from 0.25 to 4 mg/kg, SD6 attenuated arterial and cortical venous thrombosis in FeCl-induced and photochemically induced mice, without impacting hemorrhage risk, and further mitigated cerebral inflammatory injury in a mouse model of transient middle cerebral artery occlusion ischemic stroke. These findings suggest that SD6 may serve as a potential therapeutic agent for the treatment of thromboinflammatory conditions.